Laboratory of Cellular Oncology, National Cancer Institute/National Institutes of Health, Bethesda, MD 20892, USA.
Cell Host Microbe. 2010 Sep 16;8(3):260-70. doi: 10.1016/j.chom.2010.08.003.
Using a human papillomavirus (HPV) cervicovaginal murine challenge model, we microscopically examined the in vivo mechanisms of L1 virus-like particle (VLP) and L2 vaccine-induced inhibition of infection. In vivo HPV infection requires an initial association with the acellular basement membrane (BM) to induce conformational changes in the virion that permit its association with the keratinocyte cell surface. By passive transfer of immune serum, we determined that anti-L1 antibodies can interfere with infection at two stages. Similarly to active VLP immunization, transfer of high L1 antibody concentrations prevented BM binding. However, in the presence of low concentrations of anti-L1, virions associated with the BM, but to the epithelial cell surface was not detected. Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo.
我们使用人乳头瘤病毒(HPV)宫颈阴道鼠类挑战模型,通过显微镜检查 L1 病毒样颗粒(VLP)和 L2 疫苗诱导的感染抑制的体内机制。HPV 感染需要与无细胞基膜(BM)的初始关联,以诱导病毒粒子的构象变化,从而允许其与角蛋白细胞表面结合。通过免疫血清的被动转移,我们确定抗 L1 抗体可以在两个阶段干扰感染。与主动 VLP 免疫接种类似,高浓度的抗 L1 转移可阻止 BM 结合。然而,在低浓度抗 L1 的存在下,与 BM 结合的病毒粒子,但未检测到与上皮细胞表面结合。无论浓度如何,L2 疫苗诱导的抗体允许 BM 结合,但阻止与细胞表面结合。因此,我们揭示了疫苗在体内抑制病毒感染的不同机制。